The MI Molecular Intelligence Profile Test, available at DNA Labs UAE, represents a cutting-edge diagnostic approach that leverages advanced molecular analysis to uncover detailed insights into an individual’s genetic makeup. Priced at 117,000 AED, this comprehensive test is designed to identify genetic predispositions to various health conditions, potential responses to certain medications, and overall genetic health risks. By analyzing an individual’s DNA, the MI Molecular Intelligence Profile Test can provide personalized recommendations for lifestyle adjustments, dietary changes, and preventive measures to optimize health and well-being. DNA Labs UAE, known for its state-of-the-art facilities and expert team, ensures a thorough and accurate analysis, making the MI Molecular Intelligence Profile Test a valuable tool for those seeking to understand their genetic profile and take proactive steps towards personalized healthcare.
The NGS TP53 Mutation Analysis Test, available at DNA Labs UAE for a cost of 42,000 AED, is a sophisticated genetic testing procedure designed to identify mutations in the TP53 gene. This gene plays a crucial role in regulating cell division and preventing the development of tumors, making its analysis vital for understanding individual cancer risks and for the diagnosis of certain genetic disorders, such as Li-Fraumeni syndrome. Utilizing Next-Generation Sequencing (NGS) technology, the test offers a comprehensive examination of the TP53 gene, allowing for the detection of both known and novel mutations with high precision and accuracy. The results from this test can provide essential information for personalized treatment planning, including decisions regarding surveillance, surgery, chemotherapy, or radiation therapy, enhancing the potential for positive patient outcomes. Conducted at DNA Labs UAE, a facility known for its state-of-the-art genetic testing services, the NGS TP53 Mutation Analysis Test represents a significant advancement in the field of personalized medicine and genetic diagnostics.
The Oncomine Comprehensive Plus Panel Test is a cutting-edge genetic test designed to provide a comprehensive analysis of cancer-related genes. This test, performed by DNA Labs UAE, is aimed at identifying genetic mutations and alterations in a wide array of genes associated with different types of cancer. With a cost of 39,000 AED, it offers an extensive assessment that helps in guiding personalized treatment plans for cancer patients.
The test utilizes next-generation sequencing (NGS) technology to examine a broad panel of genes for mutations that could influence a patient’s response to certain cancer therapies, making it an invaluable tool in the realm of precision medicine. By pinpointing specific genetic mutations, healthcare providers can tailor treatments to the individual’s genetic profile, potentially improving outcomes and minimizing unnecessary side effects.
The Oncomine Comprehensive Plus Panel Test is particularly useful for patients with advanced or difficult-to-treat cancers, where conventional treatment options may have been exhausted or are deemed less effective. The insights gained from this test can lead to the identification of targeted therapies and clinical trial opportunities that are most likely to benefit the patient based on their unique genetic makeup.
DNA Labs UAE, known for its state-of-the-art facilities and expertise in genetic testing, ensures that the test is conducted with the highest standards of accuracy and reliability. Their team of specialized geneticists and clinicians work closely with patients and healthcare providers to interpret the results and integrate them into the patient’s care plan.
In summary, the Oncomine Comprehensive Plus Panel Test offered by DNA Labs UAE is a significant advancement in cancer care, providing a deeper understanding of the genetic underpinnings of an individual’s cancer and opening up personalized treatment avenues. With its comprehensive approach and the high cost reflective of its extensive analysis, it represents a crucial step forward in the fight against cancer.
The Non-Invasive Prenatal Paternity (NIPT) DNA Test is a groundbreaking procedure offered by DNA Labs UAE, designed to determine paternity with high accuracy during pregnancy. This test is non-invasive, meaning it poses no risk to the mother or the unborn child, as it requires only a blood sample from the expectant mother and a simple swab from the potential father. The test works by analyzing the baby’s DNA found within the mother’s bloodstream, comparing it to the DNA of the potential father. This advanced technology can be performed as early as the 7th week of pregnancy, providing early and reliable answers about paternity.
The cost of the NIPT Pregnancy Paternity DNA Test at DNA Labs UAE is 7000 AED. This price reflects the sophisticated technology and expertise required to accurately analyze and interpret the results. Opting for this test at DNA Labs UAE ensures a high level of accuracy, confidentiality, and professional support throughout the process. This option is particularly appealing for families seeking early paternity confirmation, without the risks associated with invasive testing methods.
The Oncomine Comprehensive Panel, along with the Oncomine Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), and PD-L1 Test, is an advanced genetic testing suite designed for a comprehensive analysis of cancer genomes. Offered by DNA Labs in the UAE, this suite of tests provides a detailed overview of the genetic alterations in tumors, aiding in the personalized treatment of cancer patients.
The Oncomine Comprehensive Panel is a next-generation sequencing (NGS) test that identifies DNA and RNA changes across a wide array of cancer-related genes. This broad-spectrum analysis helps in understanding the molecular underpinnings of an individual’s cancer, facilitating targeted therapy decisions.
The Oncomine TMB test quantifies the total number of mutations within a tumor genome, providing an index of the tumor’s mutation burden. A high TMB is often associated with better responses to immunotherapies, making this test crucial for therapy selection.
The MSI test assesses the status of microsatellite instability in cancer cells, which is a condition of genetic hypermutability that results from the impairment of DNA mismatch repair. MSI status is a key biomarker in certain types of cancers, such as colorectal cancer, and influences treatment choices.
The PD-L1 test measures the expression of the PD-L1 protein on the surface of tumor cells. PD-L1 is a checkpoint protein that helps cancers evade the immune system. Knowing the PD-L1 status can guide the use of checkpoint inhibitor therapies, which can be effective in treating various types of cancer.
Conducted at DNA Labs in the UAE, the comprehensive suite of these tests is priced at 24,000 AED. This investment in precision medicine can significantly impact treatment strategies, offering hope for better outcomes by tailoring therapies to the specific genetic profile of a patient’s tumor.
The Oncopro NCCN Lung Cancer Panel Test, available at DNA Labs UAE, is a cutting-edge diagnostic tool designed to aid in the personalized treatment of lung cancer. This comprehensive test, priced at 23,400 AED, employs next-generation sequencing technology to analyze a patient’s tumor sample for specific genetic mutations and biomarkers identified by the National Comprehensive Cancer Network (NCCN) guidelines as relevant to lung cancer care. By pinpointing these unique genetic alterations, the test enables healthcare providers to tailor treatment strategies to the individual patient, potentially improving outcomes and reducing the likelihood of unnecessary side effects. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test represents a significant advancement in the precision medicine approach to lung cancer treatment, offering hope for more effective and personalized care.
The “Hepatitis C Viral RNA Genotype 1 NS5a Drug Resistance Test” is a specialized diagnostic procedure designed to detect resistance mutations in the NS5a region of the hepatitis C virus (HCV) genotype 1. This test is particularly crucial for tailoring the most effective antiviral therapy for individuals infected with HCV, as resistance mutations can significantly impact the efficacy of treatment regimens. The test involves analyzing the viral RNA to identify specific mutations within the NS5a protein, which plays a key role in the virus’s replication process and its resistance to NS5a inhibitor drugs.
Given the complexity and precision required for this test, it is performed at specialized laboratories equipped with advanced molecular diagnostic technologies. In the UAE, DNA Labs UAE is one of the facilities offering this cutting-edge test, ensuring high accuracy and reliability in the results. The cost for undergoing the Hepatitis C Viral RNA Genotype 1 NS5a Drug Resistance Test at DNA Labs UAE is 12,000 AED. This investment is crucial for optimizing the management and treatment of HCV, particularly for patients with genotype 1, the most common and often the most challenging to treat variant of the virus. By identifying the presence of drug resistance mutations, healthcare providers can make informed decisions on the most appropriate and effective treatment strategies, potentially improving patient outcomes and reducing the risk of treatment failure.
The “Can Assist Breast Test” is a specialized diagnostic procedure offered by DNA Labs UAE, designed to evaluate the risk of breast cancer by analyzing genetic markers. This test, priced at 15,680 AED, utilizes advanced genetic sequencing technologies to assess the individual’s susceptibility to breast cancer. It examines specific DNA segments for mutations and variations that are known to increase the risk of developing the disease. By providing personalized risk assessment, the “Can Assist Breast Test” aids in early detection and enables patients and healthcare providers to make informed decisions about preventive measures and tailored screening schedules. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test represents a significant advancement in personalized medicine and cancer prevention strategies.
The “Oncopro 350 Gene TMB and MSI Profile Test” is a sophisticated diagnostic tool available at DNA Labs UAE, designed to provide comprehensive insights into the genetic profile of a patient’s cancer. Priced at 15,210 AED, this test screens for mutations across 350 cancer-related genes, alongside assessing Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) status. These metrics are crucial for understanding the behavior of cancer at a molecular level, guiding personalized treatment strategies. The TMB evaluation helps in determining the likelihood of response to immunotherapy, while MSI status can indicate susceptibility to certain types of cancer treatments. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test represents a critical step towards tailored cancer care, offering hope for more effective and targeted therapy options.
The Oncopro Tumor Mutation Burden (TMB) Test is a cutting-edge diagnostic tool available at DNA Labs UAE, designed to assess the number of mutations within a tumor’s DNA. This test plays a crucial role in the field of oncology, as the Tumor Mutation Burden is a biomarker that can predict how well a patient might respond to certain immunotherapies. By evaluating the quantity of mutations, the test can help oncologists tailor more effective and personalized treatment plans for patients with various types of cancer.
The test involves a comprehensive analysis of the tumor tissue to quantify the mutation burden, providing valuable insights into the tumor’s behavior and its potential response to treatment. This information is pivotal for determining the suitability of immunotherapy, which works by empowering the patient’s immune system to recognize and combat cancer cells more effectively.
Administered at DNA Labs UAE, a facility known for its advanced diagnostic technologies and precision medicine, the Oncopro TMB Test is available for a cost of 14,040 AED. This investment can be a crucial step for patients seeking personalized cancer therapy options, offering a beacon of hope for improved treatment outcomes by leveraging the power of genetic insights to combat cancer.
